Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Q2 2025 Management View Stacy R. Lindborg, President and CEO, reported unprecedented improvement in overall survival for ...

Analysts expect Imunon to report an earnings per share (EPS) of $-3.09. The market awaits Imunon's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the ...

LAWRENCEVILLE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies and next-generation ...

The president and CEO of Imunon Inc. has resigned “to pursue another business opportunity,” the Lawrenceville-based biotechnology company announced March 12. Corinne Le Goff’s resignation is ...

I MUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of a late-stage trial evaluating the drug in the treatment of women with newly ...

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), ...

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025 Provided by GlobeNewswire Jul 29, 2025, 5:30:00 AM ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Imunon Inc (IMNN) reports significant progress in ovarian cancer treatment trials while navigating a tough capital market ...